Metformin reduced pro-inflammatory markers such as CCL2 and also improved oxidative stress, nitric oxide bioavailability, and endothelial dysfunction in general in a murine model of non-obese type 2 diabetes. Here, CCL2 is linked to type 2 diabetes mellitus.